Table 2.
Multivariate analysis for event-free survival in cN0/N1 patients with NSCLC who underwent neoadjuvant immunotherapy.
| Characteristics | Log(HR) | 95% CI | p-Value |
|---|---|---|---|
| Age | |||
| <65 | — | — | |
| ≥65 | −0.98 | −2.6, 0.61 | 0.227 |
| ICI types | |||
| PD-1 | — | — | |
| PD-L1 | 0.89 | −1.2, 3.0 | 0.412 |
| Neoadjuvant treatment cycle | |||
| ≤3 | — | — | |
| >3 | −0.42 | −2.5, 1.7 | 0.695 |
| Baseline N staging | |||
| cN0 | — | — | |
| cN1 | 0.23 | −1.4, 1.8 | 0.782 |
| Tumor histology | |||
| LUSC | — | — | |
| Non-LUSC | −0.37 | −2.0, 1.2 | 0.648 |
| Adjuvant treatment status | |||
| No | — | — | |
| Yes | 0.86 | −0.71, 2.4 | 0.282 |
| Resected lymph node count | |||
| Resected N1+N2 LN count | −0.01 | −0.14, 0.12 | 0.889 |
| Resected N2 LN count | 0.06 | −0.11, 0.24 | 0.489 |
HR, hazard ratio; CI, confidence interval; ICI, immune checkpoint inhibitor; PD-1, programmed death-1; PD-L1, programmed death-L1; LUSC, lung squamous cell carcinoma.